ABOUT OUR PARKINSON'S DISEASE PRODUCT

AIP-201: PET Imaging Agent for Parkinson’s Disease (PD)

We've developed a PET imaging agent that allows neurologists the ability to differentiate Parkinson's from essential tremor and other movement disorders.

AIP-201 is a PET imaging agent indicated for striatal dopamine transporter visualization.

PET scans take about 90 minutes

SPECT scans take about 3-6 hours

PET offers sensitivity two to three orders of magnitude higher than SPECT

Fluorine-18, a PET radioisotope, results in one-half the radiation dose of Iodine-123, a SPECT radioisotope

SPECT Scan
PET Scan

69-year-old female patient with essential tremor

 

AIP-201 is not approved by the U.S. Food and Drug Administration and is not marketed in the U.S.

 

A New Drug Application has been submitted to the FDA.

  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon
  • YouTube Social  Icon

Contact: 561-757-8666

© 2020 Advanced Innovative Partners, Inc., U.S.A.

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AIP Inc., its subsidiaries or affiliates. No use of any AIP trademark, trade name, or trade dress in this site may be made without the prior written authorization of AIP Inc., except to identify the product or services of the company.